Neulasta

Pegfilgrastim

Clinical data
Trade names	originally Neulasta, other brand names worldwide
AHFS/Drugs.com	Monograph
MedlinePlus	a607058
Pregnancy category	US: C (Risk not ruled out)
ATC code	L03AA13 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Biological half-life	15–80 hrs
Identifiers
IUPAC name N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
CAS Number	208265-92-3 Y
IUPHAR/BPS	6969
DrugBank	DB00019 Y
ChemSpider	none
UNII	3A58010674
KEGG	D06889 Y
ChEMBL	CHEMBL1201568 N
ECHA InfoCard	100.169.155
Chemical and physical data
Formula	C845H1343N223O243S9 + PEG
Molar mass	39,000 g/mol
NY (what is this?)

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).

In the United States as of 2015 the branded form costs between $5,327 and $8,191 a dose.

In July 2016 the US FDA rejected a biosimilar application from Sandoz.

In 2016 Coherus BioSciences is running clinical studies on its own pegfilgrastim biosimilar CHS-1701.

...
Wikipedia